Skip to main content
VCEL logo

VCEL · Vericel Corp

Track VCEL — free
$56.96 -0.46 (-0.80%) At close · Nov 13
Market Cap
$2.91B
Shares
51.03M
Volume · Nov 13 698.82K Avg daily vol (3M) 643.62K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$56.96 Open$57.66 Day$56.86–58.42 52W close$29.34–59.45 Avg vol 30d803K Short int5.4M · 10.5% of shares · 9.8d Short vol45% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 5
Earnings call
Third-quarter revenue rises 26%, prompting higher full-year guidance

Vericell Corporation reported third-quarter 2026 revenue of $85.4 million, up 26%, and raised full-year revenue guidance to $344 million to $346 million. Adjusted EBITDA rose 48% to $25.2 million, with adjusted EBITDA margin at 30%.

5 source passages
Good day and welcome to the Vericell Corporation third quarter 2026 earnings call. Total revenue in the third quarter increased 26% to $85.4 million, significantly above our guidance range, driven by strength across both commercial franchises. We are increasing full-year total revenue guidance to $344 million to $346 million from $330 to $340 million, an increase of $10 million at the midpoint of our guidance range. Gap net income increased 179% to $14.2 million, or $0.27 per diluted share, and adjusted EBITDA increased 48% to $25.2 million, expanding over 400 basis points versus the prior year. The company also delivered very strong profitability, with gross margin of more than 73% and adjusted EBITDA margin of 30%, both well above our guidance for the quarter. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue grows 26.1%; $200.0 million buyback authorized

Vericel Corporation reported 231,253 in revenue and 10,065 in net income, in thousands, for the nine months ended September 30, 2026, with revenue up 26.1%. In July 2026, the board authorized up to $200.0 million of share repurchases with no expiration date.

Revenue $85.37M ▲ 26.5% Net income $14.16M ▲ 179.1% Diluted EPS $0.27 ▲ 170.0%
Read from the MD&A section
4 source passages
Total revenue | 85,371 | 67,503 | 17,868 | 26.5% | 231,253 | 183,341 | 47,912 | 26.1% Net income (loss) | 14,161 | 5,074 | 9,087 | 179.1% | 10,065 | (6,725) | 16,790 | (249.7)% Nine Months Ended September 30, In July 2026, our Board of Directors authorized the repurchase of up to $200.0 million of the Company’s common stock, with no expiration date. Open the document at this passage
Nov 5
Current report 8-K
Revenue growth and net income surge drive raised guidance

Vericel Corporation reported third-quarter revenue growth of 26% to $85.4 million and net income growth of 179% to $14.2 million, raising full-year revenue guidance to $344 to $346 million and adjusted EBITDA margin guidance to 28%.

Financial results
5 source passages
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and business highlights for the third quarter ended September 30, 2026. Total net revenue growth of 26% to $85.4 million Net income increased 179% to $14.2 million, or $0.27 per diluted share Raised total revenue guidance to $344 to $346 million, compared to $330 to $340 million previously Raised adjusted EBITDA margin guidance to 28%, compared to 27% previously Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$324.17M
Trailing 12 months
Net income (TTM)
$33.31M
Trailing 12 months
Revenue growth YoY
+26.5%
Year over year
Operating margin
8.3%
Trailing 12 months
P / E (TTM)
87.6
Trailing earnings · reciprocal yield 1.1%
FCF yield
2.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$169.69M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+2.0%
Year over year · more shares
Price change (1Y)
+43.0%
Trailing year
Short interest
10.5%
Latest settlement · 9.8 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Jul 30, 2026
Q2 FY26

TL;DR. Vericel posted Q2 revenue of $77.5M (up 22%) driven by MACI (+23%) and Burn Care (+22%), delivered $2.2M GAAP net income and $14.3M of free cash flow, raised full-year 2026 revenue guidance to $330–$340M and authorized a $200M share repurchase program.

Bullish
  • + Q2 total revenue grew 22% to $77.5M, above guidance, driven by MACI up 23% and Burn Care up 22%.
  • + Company raised full-year 2026 total revenue guidance to $330–$340M and raised MACI and Burn Care guidance.
  • + First-half 2026 results were strong with 26% total revenue growth, 47% adjusted EBITDA growth and nearly $30M of free cash flow.
  • + NexoBrid posted record quarterly revenue of $1.5M+, up 30%+ year-over-year and quarter-over-quarter, with record ordering centers and hospital units.
Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +45%
above
Price vs 50-day avg +33%
above
RSI (14) 73
overbought
MACD trend Positive
52-week position 92%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +42%
trailing
6-month return +63%
trailing
YTD return +58%
this year
Relative strength +62%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $43 › 200d $39 — 50d above 200d
Institutional flow Accumulating
284 of 324 funds reported for Sep 30 · net +160.4K sh shares · +32 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.51% of shares out · ▲ +2.4% MoM · 9.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
324 holders — near 3-yr high, broad support
Squeeze score 84
high risk · 0–100
Fundamentals
Excellent
Revenue growth +16%
Y/Y
Gross margin 74%
expanding
EPS growth +60%
Y/Y
Free cash flow $24.7M
Valuation P/E 87.6
rich
Buyback $191.2M
remaining
Balance sheet $99.5M
net cash
Quant / Vol
risk profile
Very High
Volatility 45%
annualized · 1-yr
Max drawdown −31%
past year
ATR 4.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 4 of last 6
Latest guidance · from the Earnings Call filed Jul 30, 2026
Total revenue · full year Raised $330M – $340M
May 7, 2026 $326M – $336M changed to Jul 30, 2026 $330M – $340M
prior FY $276.26M midpoint +21.3% Y/Y
Macy revenue · full year Raised $284M – $290M
May 7, 2026 $282M – $288M changed to Jul 30, 2026 $284M – $290M
Burn care revenue · full year Raised $46M – $50M
May 7, 2026 $44M – $48M changed to Jul 30, 2026 $46M – $50M
Gross margin · full year Maintained 75%
May 7, 2026 75% changed to Jul 30, 2026 75%
Adjusted EBITDA margin · full year Non-GAAP Maintained 27%
May 7, 2026 27% changed to Jul 30, 2026 27%
Previous outlook earlier release · from the Earnings Call filed May 7, 2026

Still-open targets the latest release did not restate under the same label.

Total revenue · for the year $326M – $336M
Nexabrid BARDA procurement revenue · second half of the year $5M – $6M
BARDA revenue (nexabrid barter revenue) · H2 $5M – $6M
Burn care revenue · full year $45M
Burn care revenue · Q2 $9M
Burn care revenue · Q3 $12M
Total revenue (company) · full year $330M
Burn care revenue · Q4 $12M
Macy revenue · full year $285M
BARDA procurement revenue (nexabrid) · this year (2026) $5M – $6M
Prior guidance period ended · from the Earnings Call filed Jul 30, 2026
Total revenue · third quarter $76.5M – $78.5M
Macy revenue · third quarter $65.5M
Burn care revenue · third quarter $12M
Gross margin · third quarter 71% – 72%
Adjusted EBITDA margin · third quarter 21% – 22%
Guided vs delivered · last 6 settled
Total revenue third quarter
guided $76.5M – $78.5M
$85.37M Beat +10.2%
Total revenue full year
guided $272M – $276M
$276.26M Beat +0.8%
Total net revenue 2024
guided $238M – $242M
$237.22M Miss −1.2%
Total net revenue for 2023
guided $180M – $188M
$197.52M Beat +7.3%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+45% Bullish
Price vs 50-day avg
+33% Bullish
RSI (14)
73 Bearish
MACD trend
Positive Bullish
52-week position
92% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $43 › 200d $39 — 50d above 200d
Institutional flow Accumulating
284 of 324 funds reported for Sep 30 · net +160.4K sh shares · +32 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
10.51% of shares out · ▲ +2.4% MoM · 9.8 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
324 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $29 Now $57 · 92% Range high $59
vs 200-day avg +45% vs 50-day avg +33%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Burn Care net revenue $12M second quarter ended June 30, 2026 —
Epicel revenue growth 21% second quarter ended June 30, 2026 —
Free cash flow non-GAAP $29.4M Six Months Ended June 30, 2026 —
Gross margin 73% second quarter ended June 30, 2026 —
NexoBrid revenue growth versus prior quarter 36% second quarter ended June 30, 2026 —
NexoBrid revenue growth versus prior year 33% second quarter ended June 30, 2026 —
Non-GAAP adjusted EBITDA margin non-GAAP 19% second quarter ended June 30, 2026 —
Operating cash flow $32.6M Six Months Ended June 30, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
VCEL
Vericel Corp
this stock
$2.91B +58.2% +16.5% 87.6 10.5%
VRTX
Vertex Pharmaceuticals Inc
$136.56B +18.8% +46.2% 34.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$98.84B +23.8% +20.8% 21.1 2.1%
MRNA
Moderna, Inc.
$90.38B +657.4% +4.3% — 8.2%
CSLLY
Csl Ltd
$66.05B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
328
% held
109.2%
Reported
284 of 324
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
301
View
Short & Settlement
Short Interest Rising
Shares short
5.4M
Days to cover
9.8d
Change
+126.1K sh
View
Short Volume
Short vol %
45%
As of
Nov 13, 2026
Short Total
View
Fails to Deliver
FTD shares
301
Value
$12.1K
As of
Oct 9, 2026
View
Off-Exchange
Off-exchange %
41.9%
Week of
Oct 5, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$276.3M
Net income (FY)
$16.5M
EPS diluted
$0.32
View
Buybacks
Authorized
$200.0M
Remaining
$191.2M
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
16

Vericel Corporation reported 231,253 in revenue and 10,065 in net income, in thousands, for the nine months ended September 30, 2026, with revenue up 26.1%. In July 2026, the board authorized up to $200.0 million of share repurchases with no expiration date.

View
Proposed Sales
Value
$108.8K
Shares
1.9K
Filed
Nov 13, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Vericel to Report Third Quarter 2…
Published
Oct 22, 2026
View

Performance

5D 20D 120D MTD YTD
VCEL +4.3% +41.9% +62.9% +41.5% +58.2%
SPY +2.6% -1.2% +0.5% -0.2% +10.6%
vs SPY +1.7% +43.1% +62.4% +41.7% +47.6%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$200.00M
Spent (derived)
$8.80M
Remaining
$191.20M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 887359 CUSIP 92346J108 13F (30d) 269 filings 236 filers Visit website Investor relations